The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth.
about
Overexpression of c-Met increases the tumor invasion of human prostate LNCaP cancer cells in vitro and in vivoA phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.MACC1 - a novel target for solid cancers.Molecular targets and pathways involved in liver metastasis of colorectal cancer.Immunotherapies: Exploiting the Immune System for Cancer Treatment.The Role of PI3K in Met Driven Cancer: A RecapExpanding the Boundaries of Biotherapeutics with Bispecific Antibodies
P2860
Q34141440-33D2DB13-AEDF-490C-ADD8-91FD2FD329E7Q37222790-7809F394-FB80-4AC6-AB65-3F377CFB997AQ38118345-EC9306A5-FDD5-404A-902D-CC944F37028CQ38535666-B97E45B9-DEFC-433F-9D5F-F58253C6DBF0Q55362851-DF9D910B-4B16-4A04-80C0-CB9CC595D7D3Q58566840-B03C09A5-6B12-48F0-8E9D-825AD0FEDE96Q58724935-6D57FB51-FC7A-4F00-BEEE-91F62ABCEEBD
P2860
The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth.
@en
type
label
The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth.
@en
prefLabel
The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth.
@en
P2093
P2860
P356
P1476
The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth.
@en
P2093
Achim Krüger
Florian Schelter
Paolo Luraghi
P2860
P356
10.3389/FPHAR.2012.00164
P577
2012-09-11T00:00:00Z